<SEC-DOCUMENT>0000950170-24-047941.txt : 20240425
<SEC-HEADER>0000950170-24-047941.hdr.sgml : 20240425
<ACCEPTANCE-DATETIME>20240425083010
ACCESSION NUMBER:		0000950170-24-047941
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20240425
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240425
DATE AS OF CHANGE:		20240425

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Candel Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001841387
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				522214851
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40629
		FILM NUMBER:		24873140

	BUSINESS ADDRESS:	
		STREET 1:		117 KENDRICK STREET
		STREET 2:		SUITE 450
		CITY:			NEEDHAM
		STATE:			MA
		ZIP:			02494
		BUSINESS PHONE:		617-916-5445

	MAIL ADDRESS:	
		STREET 1:		117 KENDRICK STREET
		STREET 2:		SUITE 450
		CITY:			NEEDHAM
		STATE:			MA
		ZIP:			02494

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Candel Therapeutics, Inic.
		DATE OF NAME CHANGE:	20210120
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>cadl-20240425.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-04-24T18:54:33.3774+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:cadl="http://www.candeltx.com/20240425" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_736da2a0-1fd9-4561-9553-f35d54f30b08" name="dei:AmendmentFlag" contextRef="C_d3732cf2-0aa7-4303-80ee-2bad90413315" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric id="F_01186140-8cb1-45f4-860e-3e2a973bf037" name="dei:EntityCentralIndexKey" contextRef="C_d3732cf2-0aa7-4303-80ee-2bad90413315">0001841387</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="cadl-20240425.xsd"/></ix:references><ix:resources><xbrli:context id="C_d3732cf2-0aa7-4303-80ee-2bad90413315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001841387</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-25</xbrli:startDate><xbrli:endDate>2024-04-25</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <div style="min-height:0.5in;"></div>
  <p style="border-top:1.5pt double;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">WASHINGTON, D.C. 20549</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fdb7101d-57a8-41f2-8e44-710e799d3a39" contextRef="C_d3732cf2-0aa7-4303-80ee-2bad90413315" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">8-K</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">CURRENT REPORT</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_89efac23-da01-41fd-828d-9df0c389158d" contextRef="C_d3732cf2-0aa7-4303-80ee-2bad90413315" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">April 25, 2024</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_082542ba-43ab-4d94-a28e-582e2a278c98" contextRef="C_d3732cf2-0aa7-4303-80ee-2bad90413315" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;min-width:fit-content;">CANDEL THERAPEUTICS, INC.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Exact name of Registrant as Specified in Its Charter)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:33.333%;"/>
    <td style="width:33.333%;"/>
    <td style="width:33.333%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_a2adb8f9-b1ec-4030-b154-8752668419d1" contextRef="C_d3732cf2-0aa7-4303-80ee-2bad90413315" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_ed401d4f-8e79-48ed-9298-f9af9c850cae" contextRef="C_d3732cf2-0aa7-4303-80ee-2bad90413315" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">001-40629</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_164afc2a-44c3-4815-bc4a-4ccc5a954827" contextRef="C_d3732cf2-0aa7-4303-80ee-2bad90413315" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">52-2214851</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(State or Other Jurisdiction</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">of Incorporation)</span></p></td>
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Commission File Number)</span></p></td>
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(IRS Employer</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_90a4a44e-7a18-4658-ae69-eecb6994465e" contextRef="C_d3732cf2-0aa7-4303-80ee-2bad90413315" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">117 Kendrick St</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">., </span><span><ix:nonNumeric id="F_262913a1-d3de-4735-8381-b974e0a21560" contextRef="C_d3732cf2-0aa7-4303-80ee-2bad90413315" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Suite 450</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span><ix:nonNumeric id="F_4336ee6c-9d6a-4185-82c5-22cab62a41bd" contextRef="C_d3732cf2-0aa7-4303-80ee-2bad90413315" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Needham</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_8ef68b75-13fa-4149-859e-66da8d14102f" contextRef="C_d3732cf2-0aa7-4303-80ee-2bad90413315" name="dei:EntityAddressStateOrProvince"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">MA</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_78fa176b-11ac-4e90-aae4-adddb6b12204" contextRef="C_d3732cf2-0aa7-4303-80ee-2bad90413315" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">02494</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Registrant&#8217;s Telephone Number, Including Area Code: </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e154cbdc-cf06-452d-afe1-ddea4ae7c124" contextRef="C_d3732cf2-0aa7-4303-80ee-2bad90413315" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(617)</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1127cdbe-065c-4ab9-bda5-59ebb99e9f5b" contextRef="C_d3732cf2-0aa7-4303-80ee-2bad90413315" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">916-5445</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not Applicable</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;"/>
    <td style="width:96%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_202f228c-2458-4698-8e3b-bfc148f5a9c0" contextRef="C_d3732cf2-0aa7-4303-80ee-2bad90413315" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_23e5881c-e5aa-45c0-81cf-7c6971cc5c23" contextRef="C_d3732cf2-0aa7-4303-80ee-2bad90413315" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_85c90dba-4990-457a-8657-2eebff7524fe" contextRef="C_d3732cf2-0aa7-4303-80ee-2bad90413315" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_a841a9d5-5e83-41aa-a536-e6b63dfc2ab6" contextRef="C_d3732cf2-0aa7-4303-80ee-2bad90413315" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:38%;"/>
    <td style="width:1%;"/>
    <td style="width:15%;"/>
    <td style="width:1%;"/>
    <td style="width:45%;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Title of each class</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Trading</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Symbol(s)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_4e0d95cb-2bf5-4067-b6bd-e653281c64b9" contextRef="C_d3732cf2-0aa7-4303-80ee-2bad90413315" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Common Stock, $0.01 par value per share</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_ef09d946-8742-4910-ab82-489b2edba825" contextRef="C_d3732cf2-0aa7-4303-80ee-2bad90413315" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">CADL</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_c26c6a40-9a6d-41c5-b084-807908ecaf1e" contextRef="C_d3732cf2-0aa7-4303-80ee-2bad90413315" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">The Nasdaq Global Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8201;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8201;240.12b-2 of this chapter).</span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Emerging growth company </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_51331941-e85a-46d3-8931-d4a58772fede" contextRef="C_d3732cf2-0aa7-4303-80ee-2bad90413315" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b2a90c0c-b413-4038-b0e4-66a1b8147c55" contextRef="C_d3732cf2-0aa7-4303-80ee-2bad90413315" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1.5pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 7.01 Regulation FD Disclosure.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On April 25, 2024, Candel Therapeutics, Inc. (the &#8220;Company&#8221;), announced that it will present two poster presentations at the 2024 American Society of Clinical Oncology Annual Meeting taking place May 31 to June 4, 2024, in Chicago, IL. The first presentation will feature data from the ongoing phase 1 clinical trial of CAN-3110 in patients with recurrent high-grade glioma. The presentation will focus on patients recruited in cohort C, treated with multiple injections of CAN-3110 (up to six), demonstrating that this approach is both feasible and well tolerated. The second presentation will show topline overall survival data from the phase 2 clinical trial of CAN-2409 plus valacyclovir, in combination with continued immune checkpoint inhibitor treatment in patients with non-resectable, stage III/IV non-small cell lung cancer who have an inadequate response to front line anti-PD(L)1 therapy.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A copy of the full press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information in this Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K shall not be deemed to be &#8220;filed&#8221; for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section. The information in this Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report on Form 8-K, regardless of any general incorporation language in any such filing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9.01 Financial Statements and Exhibits.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(d) Exhibits</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:7.08%;"/>
    <td style="width:2.02%;"/>
    <td style="width:90.9%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;99.1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span><a href="cadl-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Press Release dated April 25, 2024</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;104</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGNATURES</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.46%;"/>
    <td style="width:5.04%;"/>
    <td style="width:3.04%;"/>
    <td style="width:46.46%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Candel Therapeutics, Inc.</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: April 25, 2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Paul Peter Tak</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Paul Peter Tak, M.D., Ph.D., FMedSci</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">President and Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>cadl-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-style:italic;min-width:fit-content;">Exhibit 99.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img160460863_0.jpg" alt="img160460863_0.jpg" style="width:222px;height:99px;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:14pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Arial;min-width:fit-content;">Candel Therapeutics Announces Upcoming Presentations</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Arial;min-width:fit-content;">at the 2024 ASCO Annual Meeting</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">NEEDHAM, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that two abstracts were accepted for presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 to June 4, 2024, in Chicago, IL. The first presentation will feature data from the ongoing phase 1 clinical trial of CAN-3110 in patients with recurrent high-grade glioma. The presentation will focus on patients recruited in cohort C, treated with multiple injections of CAN-3110 (up to six), demonstrating that this approach is both feasible and well tolerated. The second presentation will show topline overall survival data from the phase 2 clinical trial of CAN-2409 plus valacyclovir, in combination with continued immune checkpoint inhibitor (ICI) treatment in patients with non-resectable, stage III/IV non-small cell lung cancer (NSCLC) who have an inadequate response to front line anti-PD(L)1 therapy.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Details are as follows:</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">CAN-3110 &#x2013; Recurrent High-Grade Glioma</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">Trials-in-Progress Poster Presentation Title: </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Longitudinal stereotactic injections of oncolytic immunoactivating rQNestin34.5v.2 (CAN-3110) with concomitant biopsies for &#x201c;-omic&#x201d; analyses in recurrent glioblastoma (GBM).</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">	                                                          	</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">Presenter: </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">David A. Reardon, MD, Professor of Medicine at Harvard Medical School; Clinical Director, Center for Neuro-Oncology at Dana Farber Cancer Institute 											</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">Session Title: </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Poster Session &#x2013; Central Nervous System Tumors </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">			</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">Session Date/Time:</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;"> Saturday, June 1, 2024; 9:00 AM - 12:00 PM CT </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">	</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">	</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">Location:</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;"> Hall A, McCormick Place Convention Center, Chicago, IL </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">CAN-2409 &#x2013; Non-Small Cell Lung Cancer</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">Poster Presentation Title: </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Overall survival after treatment with CAN- 2409, plus valacyclovir in combination with continued ICI in patients with stage III/IV NSCLC with inadequate response to ICI. 							</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">	</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">Presenter:</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;"> Charu Aggarwal, MD, MPH, Associate Professor for Lung Cancer Excellence, Perelman School of Medicine, University of Pennsylvania </font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">Session Title:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Poster Session &#x2013; Lung Cancer &#x2013; Non-Small Cell Metastatic </font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">Session Date/Time: </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Monday, June 3, 2024; 1:30 PM - 4:30 PM CT </font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">Location: </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Hall A, McCormick Place Convention Center, Chicago, IL </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Full abstracts will be released by ASCO on Thursday, May 23, 2024, at 5:00 PM ET. Details from the presentations will be available following the events on the Candel website at </font><font style="color:#ed7d31;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">https://www.candeltx.com/media/</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">About CAN-2409</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">CAN-2409, Candel&#x2019;s most advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus designed to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient&#x2019;s tumor and induce an individualized, systemic anti-tumor immune response. HSV-tk is an enzyme that locally converts orally administered valacyclovir into a toxic metabolite that kills nearby cancer cells, resulting in the release of a wide variety of cancer antigens. At the same time, the adenoviral serotype 5 capsid protein has the potential to elicit a pro-inflammatory response in the tumor microenvironment. Together, this regimen is designed to induce an individualized and specific CD8+ T cell mediated response against the injected tumor and uninjected distant metastases for broad anti-tumor activity, based on in situ vaccination against a variety of tumor antigens. As a result, CAN-2409 is an off-the-shelf drug candidate designed to result in an individualized anti-tumor immune response with the potential to treat a broad range of solid tumors. Encouraging monotherapy activity, as well as combination therapy activity with Standard of Care (SoC) radiotherapy, surgery, chemotherapy, and ICI, have previously been shown in several preclinical and clinical settings. Furthermore, to date, more than 1,000 patients have been dosed with CAN-2409 with a favorable tolerability profile supporting the potential for combination with other therapeutic strategies without inordinate concern of overlapping adverse events.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Currently, Candel is evaluating the effects of treatment with CAN-2409 in NSCLC, borderline resectable pancreatic ductal adenocarcinoma (PDAC), and localized, non-metastatic prostate cancer. CAN-2409 has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for treatment of PDAC, stage III/IV NSCLC in patients who are resistant to first line PD-(L)1 inhibitor therapy and who do not have activating molecular driver mutations or have progressed on directed molecular therapy, and treatment of localized, primary prostate cancer in combination with radiotherapy to</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">improve the local control rate, decrease recurrence and improve disease-free survival. Candel&#x2019;s pivotal phase 3 clinical trial in prostate cancer is being conducted under a Special Protocol Assessment by FDA. The FDA has also granted Orphan Drug Designation to CAN-2409 for the treatment of PDAC.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">About CAN-3110</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">	</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">										</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">CAN-3110 is a first-in-class, replication-competent herpes simplex virus-1 (HSV-1) oncolytic viral immunotherapy candidate designed with dual activity for oncolysis and immune activation in a single therapeutic. Its activity is designed to be conditional to the expression of Nestin in cancer cells. CAN-3110 is being evaluated in a phase 1b clinical trial in patients with recurrent HGG (rHGG). In October 2023, the Company announced that </font><font style="color:#ed7d31;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-style:italic;min-width:fit-content;">Nature</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">published results from this ongoing clinical trial. CAN-3110 was well tolerated with no dose-limiting toxicity reported and CAN-3110 plus prodrug was associated with improved survival. Positive HSV-1 serology was a predictor of response and was associated with improved survival. Increased infiltrating immune cells in the tumor microenvironment and expansion of the T cell repertoire after treatment were also associated with improved survival. In the clinical trial, the investigators observed a nearly doubling of the expected median overall survival after a single CAN-3110 injection compared to historical reports of less than 6 to 9 months in this therapy-resistant condition. By comparison, survival in the anti-HSV1 positive patients treated with CAN-3110 was more than 14 months. The Company and academic collaborators are currently evaluating the effects of multiple CAN-3110 injections in rHGG, supported by the Break Through Cancer Foundation.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">For more information about Candel, visit</font><font style="color:#002060;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">: </font><font style="color:#ed7d31;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">www.candeltx.com</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">Forward-Looking Statements</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">This press release includes certain disclosures that contain &#x201c;forward-looking statements,&#x201d; within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of development programs, including the timing and availability of additional data; and expectations regarding the therapeutic benefit of the Company&#x2019;s programs, The words &#x201c;may,&#x201d; &#x201c;will,&#x201d; &#x201c;could,&#x201d; &#x201c;would,&#x201d; &#x201c;should,&#x201d; &#x201c;expect,&#x201d; &#x201c;plan,&#x201d; &#x201c;anticipate,&#x201d; &#x201c;intend,&#x201d; &#x201c;believe,&#x201d; &#x201c;estimate,&#x201d; &#x201c;predict,&#x201d; &#x201c;project,&#x201d; &#x201c;potential,&#x201d; &#x201c;continue,&#x201d; &#x201c;target&#x201d; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management&#x2019;s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; the Company&#x2019;s ability to continue as a going concern; expectations regarding the therapeutic benefit of the Company&#x2019;s programs; that final data from the Company&#x2019;s pre-clinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Company&#x2019;s ability to efficiently discover and</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">develop product candidates; the Company&#x2019;s ability to obtain and maintain regulatory approval of product candidates; the Company&#x2019;s ability to maintain its intellectual property; the implementation of the Company&#x2019;s business model, including strategic plans for the Company&#x2019;s business and product candidates; and other risks identified in the Company&#x2019;s filings with the U.S. Securities and Exchange Commission (SEC) including the Company&#x2019;s most recent Annual Report on Form 10-K filed with the SEC and subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company&#x2019;s views only as of the date hereof and should not be relied upon as of the hereof date and should not be relied upon as representing its views as of any subsequent date.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">Investor Contact</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Theodore Jenkins</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">VP, Investor Relations and Business Development</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Candel Therapeutics, Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#ed7d31;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">tjenkins@candeltx.com</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">Media Contact</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Aljanae Reynolds</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Wheelhouse Life Science Advisors</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#ed7d31;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">areynolds@wheelhouselsa.com</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img160460863_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img160460863_0.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #B ?T# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBF2S)!&TDC*B*,EB>E #FY&*^9
M_B1X-M?A9\0S\0M0U>:ZCDN=\&GPQXED<KC9OSC: /RXKW[0?&&B^)VF32M3
MM;]H3AQ;RA]OUQ6=\1/ASI7Q*T4:?JBNHC;S(IHFVNC>H_,C!]:\?'4%C:/-
M2LY+6/J>O@,0\%7Y:UU&6DN]BG\*_BE8?%/1IKRS@DM9;>3RYH)<94]1@C@@
MC^1KM99%AC:1SA%!)/L*^5[/XD0? WQHW@_0]&^T62W"+=7$[DSSNP'S+C@
M @ >QKZFVK<0D,,JRX(/O4Y;C'B*;IS=ZD='VN7F6#6&J*<4U3GK&^]CSOP-
M\>/#GC[Q%<:/8&X2XC#-&\R;4E /)7G^>*W_ (E>"T^(/A"]T5[DVGG@$3*,
M[2#D$CN.*PO#OPI\&_"[4;O7($6SDDR/-NI_DB!/1<\"N^W0ZE9YCD$D,R\/
M&V00>X(K6A&K5HRI8MIR=]NQC7G1I5HU<'=15M7W/&_V?O"^@^!;C5M+M/$M
MKK.LR,/M$4! \L+D8"Y)ZDYKN/BSX$G^(G@R[T>VNQ9SR%65VSM)!SAL=CBN
M \&_#7PC\,?B<UP_B(/J]YO-K8SNJL YY]SWQ7J7CS5]0T/PCJ=_I-M]LOX8
M&>&$ G+ >@ZUQX2G&."G0JQLE=63Z?YG;BZDI8V->C-MNSNU;7_(Y[X+?#.?
MX7^%WT^ZO5O)Y)3*_E@A%SV7-;WQ$729O!^I1:W=BQTV2(I-,6QM!KG?@;XL
M\1^,/"\MYXCLOLET)2L;>68_,7UVGI5WXQ67AS4_!L]GXFU%=,T^5U GW[2&
MSQCUKHINFL#^Y5E;1/\ 4YJGM'CW[>5Y7U:U^XX_]GSX:^'?#JW>MZ'KAUY;
MC]T)@H4(H/3'K7J_B+5SH&@W^HB)K@VL#S"->K;5SC]*YSX3^!-(\"^&([?1
MKE[VUN#YWVEV#>9GOQQ6CXP\?>'_  6D"Z[?Q68NFV(K@G=^ [4\+3CA<&HN
MT-/DFQ8JI+%XQR5YZ_-I>AYU\#_CIJ'Q0UK4;&]TR*U$"B6.6%B0%)QM;/?_
M .O7M)[FLG0=%T?386GTJSM;:.X_>%[>-4#Y[G'UKFOC!_;5]X,O[/PY<"/5
MW7Y51PLA7^(+[XK2DZN%PSE6ESM:^I%;V6*Q*C1CR1>FO0\.^/'Q&\;:9\1'
MTW3IKBVL-J+;P1Q!TN<@9!R#NR<C%?1/@/0[?1/#EIY6F6^ESS1K)<0V\80;
MR.>!7G'[.?AWQ5I^DWK>*A<,OG!K2.^;?*G'S')R0#]?6O:O:N#+,/.4I8NJ
MW[VR?0[\TQ$(QC@Z27N;M?:%HHHKZ,^<"BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** .8E^(6C6_BB[T*>X,-[:VXN96D7;&J$X^\>/
M3\Q71PSQW$221,LD;#*LIR"/:L#QMX$TOQYHESIFI1L(9]NZ2$[7^4@CGZUY
M#J-KXO\ A#X@N]8>Z:;P%I5JL<%BCAF90@55P1G.[DMZ5Y5;$U<+*]2-X=UT
M]3U:.&I8J-J<K3[/KZ>;/H&L#QUX?D\5^$]5TB*X-K+>0/"LH_A)!KCOA[\=
MM'\7>&9]7U+R] 2&;[.RW4HV,V,C:QQG@_I7H]AJ%MJEG'=6<\=S;2C<DL;!
ME8'T-=%.M1QE.T)737X'/4HU\'4]^-G%_B>&? KX&ZK\,]>OM7UF\MPI@,*1
MP,2N,@EB2!Z=/>O8- \9Z+XJDG32=3MK]H#ME6WD#E/KC_/%6?$>CKXBT&_T
MV21H5NX7A+H>5W#&1^=>8?!CX$GX4ZC?ZC<ZF+V:6/R4")L54!SD^_3Z<UY]
M&C/ 2AA\/"]/6[OL=]:O#,(U,1B9VJ:65M&=9\0/#MO#I]]X@L-#M=1\1VL#
M-:R/$"^X#C!ZURG[/?BSQ=XHT_5)/%,+1K'(HMY)(?*9L@[ACN!QS[UZ'X?\
M;:'XLENH])U*WOWMFVRK#(&VGW_7\C7"?&CPCXW\1WVC-X4U3[!;PN3<*LAC
M.<C#'^\!SQ[T5X\DUBZ#;2Z1Z^84)<T'A*Z2;^U*^ENGS-?XQ_"P_%/08+!=
M0:QDAE$JMMW*< C!&1ZUT/@/PJG@CPII^B).UTMI'M\U^"QSGI6O82;H4C:=
M9IXU D93_%CGC_/6O.8],^('_"W'NI+R,>#]G$.5Y^7IC&[.>_2NF<*=*JL1
M&#<I66G0YX3J5J+P\II1C=J_5^1#X\^&W@]/&-EXQU[4FL)87C55EG5(I'!^
M7.1G\C7I%]J4%AI$]^QWV\,)FRG.5 SQZUS_ ,1O V@>-M'C3Q"=EI:.)Q+Y
MOEA".Y/3&,_G6Y9R:=:Z'$T$D1TR*#Y7#;D\L+Z^F*JG3]G4GRI)/7SOYF=2
MK[6G3YFVUI;I;R.8^%OQ2L/BA8WEU8VL]J+:7RV68 9]",$BLSXT:5X0\1:?
MI^E^*=3_ +-:2<&V99 C%NG&01W]*ZKP5J7AW5M*>X\-M:-9&1@YLU55W=\X
M'6L;Q;H/@WQKXEL=-UAK>ZUFS_?PVOG;9 /4J#R*SG&4\,H2:DWWV9K"4*>*
M<XIQ2[;HZ?PWHMIX=T.RTVQS]DMXPD>XYX'O7+_$3X0Z%\3I[&;5#,LEHW#0
M/MW#NIX/%=LT?EV_EQ?)A=J>WI7G/PN\'^,/#FN:W<^(]<_M*TN7S;Q;RP3G
MKR!MXQP*VK1BU&A*G>+^Y6,J,YQ<J\:G+)?>[G=%]/\ #.DIYDL=G8VR!=\K
M;550,<D_A7B=]\'=7\3?%RU\86.N0S:,94G1DD);:!]P <8/U[UVOCB/PW\6
MDU'P5_;(BU&';))'"<NA![CH<=Q72_#_ ,$VOP_\,6FBVDTEQ%;Y_>2=22<G
MITYS7+5HQQDU3:O".J:?5=#IHUY8.G*I&5JDM&FNCZW.C5=J@>@Q2T45[1XP
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %07
MEG!J%K+;W4*7$$BE7CD4,K ]00>M3T4FD]&--WNCP+XY? :\\46NCIX4@M;:
MWLO,5K%<1)EL?..V>*Y6_P#B%K7[.6AZ)X42TBO[QD:ZGED=O+7<Y_=Q\?7G
MWZ5]3$A5Y.!61JWA?1O$KPR:A86NH-"<QM-&K[?I^E?/8C*ESRK867)4E]Q]
M%A\V?LXT,7'GIQN_._J1:#XJM=7TC3+J5TLY[Z!)EMY7 <;E!Q@\\9K5OK5-
M0LYK>49BF0HV#V(P:\7\?? 74?%GQ-L/$%OJRVUC"8]T7S;X]ASA,<<UMV_Q
MI+_%H^"O[(F\M/D^V9[[-V<8Z>^:Z88N4&Z>)C97LGW_ ,CDEA(U$IX65W9R
M:_E_S+7PO^".D_"N\O[RUNY[J2X 7=-@"- <XX_#GVKK?#WC31/%LEW%I.I0
M7[VK;)A"X;8>>OZ_E6RWESJ\196!&UE!]:\V70/"OP!T/6-<M;2=8IF4RK'F
M1CEN%'H,L:U4%A(QC125-7N9.H\9*4JS;J.UB7P?\.=.^%>K:YKESKLDD>I2
M[F^V.$2/+9 R3R><5O\ Q"7Q%=^%)_\ A$IH$U9RIBDEP5VYYZ\=,TS4M'T;
MXM>#[7[9;O+I]T$N$1LHPZ$9KI;.TCT^TBMH%V0PH$1<] !@"M*=%*#IPT@]
MGUU,ZE9\ZJ5-9IZIK30PI_#+>*O!:Z/XE"W$EQ J7?DDJ&; SC'O5W2?"^G:
M-X=BT2WAQIT<1A$+'/RGJ/Y_G6N3MY/%<7XP^-'@;P!C_A(?%6DZ23GBYNT4
M\>V:ZXT(WNE=[7\CEE6G:U[*][>9M>%_"&E>"]/^P:/:):6Q<N57)RQ[\TW_
M (0O1QXF/B 64?\ :WE^5]IYW;?2O)E_;@^"+7'D_P#"P=*#9QN,GR_GC%>A
M>#_C'X'\?9_X1[Q5I.KD?PVMVCG\LU;PR44G#1;:"]O*4G+FU>XGQ*\.>)/$
M5C8Q^'=:_L:6.=7F;9G>@/(K5\0^*K+P)X=&HZW=$0Q;8WE5"2S'CH*W\AAD
M'(JO>6%OJ-N8;J".YA.,QRJ&4X]C6#I6<IP>K[[&D:J:C":T7;<YGP]X$\-V
M^OS>*M.LU34+]-S7&YOF!P<[3P,\5U],1%C554!5'  I]:4Z<::LE;_,BI4E
M4=V[^H4445J9!16=X@\0:=X5T6\U?5KR+3]-LXVFN+JX;:D:#J236+\.?BCX
M6^+6@_VSX4UFUUK3Q(T1FMGW!7'52.QY'YU5GOT ZNBBBI **** "BBO./''
M[0OP\^''BZP\,^(_%%AI6N7VPPVL\F&(=MJD^@)Z9JDK[!>QZ/1358, P.0>
M1BG5(!1110 45#>7D%A:RW-S*D$$2EY)9&"JBCDDD]!7+VWQ<\%W=Q'!!XJT
MB661@J(M[&2Q/0#GK346]@.NHI/3FEI %%%5M0U*UTBRFO+ZXCM+6%=TDTSA
M$0>I)H LT5QG_"YO O\ T-NC?^!L?^-'_"YO W_0V:/_ .!L?^-7R2["NCLZ
M*XY/C%X'D<*OBS1RS' 'VV/_ !KHM-U[3-84-8ZA:W@/_/"97_D:7*^P71?H
MHHJ1A1110 4457U#4+;2[.6[O;B.UMHEW22S,%11ZDGB@"Q17&_\+D\"_P#0
MVZ/_ .!L?^-)_P +F\#?]#9H_P#X&Q_XU?)+L*Z.SHKC/^%S>!O^ALT?_P #
M8_\ &E_X7-X%_P"ALT?_ ,#8_P#&CDEV"Z.RHKFM%^)7A;Q%?)9:9XATV^NV
M!*PV]TCN<=< '-=+4M-;C"BBBD 45D^(/%6C^%;>.?6-3M=,BD;:CW4RQACZ
M DC-5-!^('AKQ1=M:Z1KNGZE<JN\Q6MRCOCUP#3Y7:X'0T444@"BBB@ HKBO
M$WB;Q)HNK7OV30A?:5!ISW*3)+^\DG!XB"^X%<++^T/>Z6WAJVU3PQ>6]_JW
M^LB'_+(>84&,\D\;L>A%>?5QU&B[5-/DST*6!K5E>FD_FCVZE]Z\M\/_ +0?
MAW7O%=_HB>;"UHLC&XD7$;>7]_!]N>OI5KP/\=O#7C[7I=*T^:1;E5+1^<A4
M2J.I7Z=:4<PPLVDJBUT0Y9?BJ:<I4W9*[]#9^*VDZQK?@/5;+09O)U25 (F#
M;3U&0#V)&1GWKC_V=_"/BGPEH.H1^)99/WLH:"":7S&0 <G.3U/;VKTC2_%.
MDZY=3VUAJ%O=S0'$L<,@8J??%:NX-D @^HI/#TZN(CB8R=UIOH"Q-2CAY85Q
M5F[[:GFGAOXZ:-XE^(5UX6MXIUN(6D19V7Y'9/O =^Q_*O0CIUI]J-UY,2W3
M+L\[:-^/KUK(T_P#X?TG7KC6[32X8=3GSYEPH^8YZ_3/>N4^+7@_Q?XFU70Y
MO#>LC3+:VD+7*;BN[D8/ ^; #<'UJ$Z]&DY5ESN^ENQ;6'K58QHODC;6_<?X
M4^&]UX+\7>(/$=WKESJ%O> NMJV2(QG=Z]L8&.U;O@?QEIOQ/\.M?06LGV1I
M&B:&[BQDK['KVJGX\^)">!]0T2RDTV[U!M2E\G=;ID)TY/YUV5M;QP1@11K$
MO7:HP.O-70C",W3I/1;KS9%:4Y052JM7L_)$D<:Q1JJ#:J\ *, 5P_QB^,WA
M;X&^#[GQ%XIU!;*UC&(XNLL[]D1>K$UT7B_Q7IO@;PSJ6OZQ<+::;I\#W$\K
M'@*HR:_#;]I_]HW6OVCOB-=ZU>S2Q:);NT>EZ<6^2"'. Q']]NI/OBO?PN']
MO+R1Y%6I[->9Z?\ M"?\%$OB#\7KRXL?#MQ)X-\-9*I#9MBZE7_;D'3/HOYU
M\KS37>KWC2323WUY(>7D9I'8_4Y-?0/[)O[''B']IC6C<L[Z/X1M9,76J,F=
MY[QQ#^)OT&:_5SX3_LI_#'X-V,,6@^%[-[R,#=J-[&)[AV'?<P./PQ7J3KT<
M+[D%J<D:=2MK)GX8MX/UY8?-;1-0$6,[C;/CZ]*HVMU=Z1>)-;RSV-W&<K)&
MS1NI]<C!K^C,V5NT>PV\13&-NP8_*O(?BO\ LC_"[XQ6,T>M^%K."]<';J&G
MQB"=6/?*X#?B#64<Q3?O1+>&=O=9^</[./\ P4<\<?"FZMM,\7RR>+_#60C-
M.V;N!?57_CQZ'GWK]6/AK\2O#_Q<\'V'B;PS?+J&E7BY21>"K=U8=01W%?F#
MXN_X)<^.]-^*MCHNB7<.H^$KR3<=:D(4VL8/(D7^]CICK7Z7?!7X/Z'\#?A_
MIOA/P_&5L[49DE<_/-(?O2-[DUS8MT96E3W9I1YUI([NBBBO,.H***J:MJEM
MH>EWFH7LRV]I:PO/-,YP$15RS'Z &GN[ ?!__!57XY?\(_X+TGX:Z?-MO-:8
M7E_L/*VR'Y%/^\X)^B5X/_P3!^.!\ _%VY\%ZA<;-(\4)B .WRI>("4_[Z7*
M^Y"U\\?M%?%Z\^.7Q@\1>+;IV\FZN#':1,<B*W3Y8U'X8S[DUPFAZU>>&]:L
M-6TZ5K:_L9TN;>9>J2(P8'\Q7TL,,E0]F]V>9*H_:<Q_1K^-%>=_L_\ Q6M/
MC5\(_#GB^U9-U_;*;B-3_JIEXD0_1@:]$KYN2<79GI)W"BBBI&%?CC_P4_\
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MXM^MO_Z.2MJ'\6/JB)_"S\4EB4D ("3[5:_L6\X_T"X_[\-_A6GX%7=XX\.
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M^38M(.5M8S]X?[SY/T45[/\ MW?!%?C5\ =9BMH/-US15.IV&T?,6C'SH/\
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MG'+U'#_5Y5&];WOJ:2S%RQ/UB--+3:VAD>)M-OM4\,WME97/V2_FMVCCN!_
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MQG\:15'^&C\YO^"BO[%OVY;WXJ>![#-RH\S7-,MD_P!8.]P@'<?Q#OUKX:^
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MFX+X!/W1G'^\:_3"NW&U^:2A!Z(PH4[*\D<A_P *>\#_ /0I:-_X!1_X4?\
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M/Q5_;9_9%OOV;O&7]H:6DEUX&U:5C8W&"3:OU,$A]OX3W ]17S?IO_(2M/\
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MXE>-K)K30K-Q-IFG7"8>[<?=D8'H@X(]2!VKZ%_9[_X)L>!_A3>6^L>*)?\
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M_P ,@_&7_HG>L?\ ?"__ !5?18:4)8?DDSSZJDJETC]1/^'D'P,_Z&2Y_P#
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M* "FM&K,"R*Q'3<.E.HH /UHHHH **** $VCTHVCTI:* $XI?7BBB@ HHHH
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M95.G.G5P\XIN2T;>UCWVBFHVY5.>2.W^?K3J^B3NKGSH4444P"BBB@ HHHH
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M (55!2C3BI;D5G&523CM<6BBBMS$**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H7H:**3&%%%%,
M04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
-%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>cadl-20240425.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-04-24T18:54:33.6715+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.candeltx.com/20240425" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:cadl="http://www.candeltx.com/20240425" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" namespace="http://fasb.org/us-gaap/2023"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.candeltx.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:roleRef roleURI="http://www.candeltx.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="cadl-20240425.xsd#DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.candeltx.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140646830487888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Apr. 25, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001841387<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Apr. 25,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CANDEL THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40629<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">52-2214851<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">117 Kendrick St<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Needham<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02494<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(617)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">916-5445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $0.01 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CADL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>7
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MR%S)%Y&&O X8EWP,$"Z_Y/)1D0!F-2IF]CYFFSH(O/^:Q9HC'.V2HWU.?$9
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M>ZC+N.HL?X;[:)'-M[#/)73)>UYN1]76^T$D7O!9QP<<GB-WPQ-',)^ Q1'
ML#P8 \PG>&%Y_J?]K-#]! SCMHHB*]1GA?H$KQBR'3Y8GKA/[I_X3O,\3;,,
MJ^AV&V6PQ>J69? 7CX9Q P\L#V1Z6ZWQ;N,3\OH<8#U];4*PG>*3B.T4KS4@
M\;J!1Y['NXWE 0^L"]CL0/YX'IBIN$^:0E<Q;M@)QI$\QQ"8Q?B,9AE2G0P^
M\?Y@IR1-\SR. !9GD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$
M%     @ Q$.96)>*NQS     $P(   L   !?<F5L<R\N<F5L<YV2N6[#, Q
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M2P$"% ,4    " #$0YE8_[7XC.\    K @  $0              @ &O
M9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " #$0YE8F5R<(Q &  "<)P
M$P              @ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0
M   ( ,1#F5C<$M-2@00  ,81   8              " @0X(  !X;"]W;W)K
M<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " #$0YE8GZ ;\+$"  #B#
M#0              @ '%#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( ,1#
MF5B7BKL<P    !,"   +              "  :$/  !?<F5L<R\N<F5L<U!+
M 0(4 Q0    ( ,1#F5@<.&7J/P$  #P"   /              "  8H0  !X
M;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #$0YE8)!Z;HJT   #X 0  &@
M            @ 'V$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"
M% ,4    " #$0YE899!YDAD!  #/ P  $P              @ ';$@  6T-O
F;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"   E%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="cadl-20240425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.candeltx.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="cadl-20240425.htm">cadl-20240425.htm</File>
    <File>cadl-20240425.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "cadl-20240425.htm": {
   "nsprefix": "cadl",
   "nsuri": "http://www.candeltx.com/20240425",
   "dts": {
    "inline": {
     "local": [
      "cadl-20240425.htm"
     ]
    },
    "schema": {
     "local": [
      "cadl-20240425.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 24
   },
   "report": {
    "R1": {
     "role": "http://www.candeltx.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_d3732cf2-0aa7-4303-80ee-2bad90413315",
      "name": "dei:EntityAddressStateOrProvince",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cadl-20240425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_d3732cf2-0aa7-4303-80ee-2bad90413315",
      "name": "dei:EntityAddressStateOrProvince",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cadl-20240425.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.candeltx.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.candeltx.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.candeltx.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.candeltx.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.candeltx.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.candeltx.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.candeltx.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.candeltx.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.candeltx.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.candeltx.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.candeltx.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.candeltx.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.candeltx.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.candeltx.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.candeltx.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.candeltx.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.candeltx.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.candeltx.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.candeltx.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.candeltx.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.candeltx.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.candeltx.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.candeltx.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.candeltx.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0000950170-24-047941-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-24-047941-xbrl.zip
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M=4ZES1BU;*Y1> IHBSM>2^?<YG@LV&KBW0-KC0,+Q%=?0)^#F1!M9;M>VM:
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M/,!'N:D\Z>/-()T]Z!Z&"R]51[BQ)AR"PQG&_RD53C8SLMUB6.[ N06*"3F
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M+7W*%%> G\=.TZ#%=HI'2I/Q#U22\72VRW8NN GY'UTVZ!^?[7J,LR"6J0P
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M?;?%GBWV% @C]/J!Y9A/9,CZ+? YN Y5ZK'S8P\@3XT  <'X 5/.12@#"ES
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M_\$T%ZX#<*<#YDX01(J*P($!Q1*$]?YTY00QYO+8IUK_^D*""D;QE@5X.U1
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MSG[^VZN]R";QS_\/4$L! A0#%     @ Q$.96/VIF7GH%   @[,  !$
M         ( !     &-A9&PM,C R-# T,C4N:'1M4$L! A0#%     @ Q$.9
M6'"/KXQ""0  WFP  !$              ( !%Q4  &-A9&PM,C R-# T,C4N
M>'-D4$L! A0#%     @ Q$.96!O5KK4D%   YG\   \              ( !
IB!X  &-A9&PM97@Y.5\Q+FAT;5!+!08      P # +L   #9,@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>cadl-20240425_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cadl-20240425.xsd" xlink:type="simple"/>
    <context id="C_d3732cf2-0aa7-4303-80ee-2bad90413315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001841387</identifier>
        </entity>
        <period>
            <startDate>2024-04-25</startDate>
            <endDate>2024-04-25</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="C_d3732cf2-0aa7-4303-80ee-2bad90413315"
      id="F_736da2a0-1fd9-4561-9553-f35d54f30b08">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_d3732cf2-0aa7-4303-80ee-2bad90413315"
      id="F_01186140-8cb1-45f4-860e-3e2a973bf037">0001841387</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="C_d3732cf2-0aa7-4303-80ee-2bad90413315"
      id="F_fdb7101d-57a8-41f2-8e44-710e799d3a39">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_d3732cf2-0aa7-4303-80ee-2bad90413315"
      id="F_89efac23-da01-41fd-828d-9df0c389158d">2024-04-25</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_d3732cf2-0aa7-4303-80ee-2bad90413315"
      id="F_082542ba-43ab-4d94-a28e-582e2a278c98">CANDEL THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_d3732cf2-0aa7-4303-80ee-2bad90413315"
      id="F_a2adb8f9-b1ec-4030-b154-8752668419d1">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_d3732cf2-0aa7-4303-80ee-2bad90413315"
      id="F_ed401d4f-8e79-48ed-9298-f9af9c850cae">001-40629</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_d3732cf2-0aa7-4303-80ee-2bad90413315"
      id="F_164afc2a-44c3-4815-bc4a-4ccc5a954827">52-2214851</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_d3732cf2-0aa7-4303-80ee-2bad90413315"
      id="F_90a4a44e-7a18-4658-ae69-eecb6994465e">117 Kendrick St</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_d3732cf2-0aa7-4303-80ee-2bad90413315"
      id="F_262913a1-d3de-4735-8381-b974e0a21560">Suite 450</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_d3732cf2-0aa7-4303-80ee-2bad90413315"
      id="F_4336ee6c-9d6a-4185-82c5-22cab62a41bd">Needham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_d3732cf2-0aa7-4303-80ee-2bad90413315"
      id="F_8ef68b75-13fa-4149-859e-66da8d14102f">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_d3732cf2-0aa7-4303-80ee-2bad90413315"
      id="F_78fa176b-11ac-4e90-aae4-adddb6b12204">02494</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_d3732cf2-0aa7-4303-80ee-2bad90413315"
      id="F_e154cbdc-cf06-452d-afe1-ddea4ae7c124">(617)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_d3732cf2-0aa7-4303-80ee-2bad90413315"
      id="F_1127cdbe-065c-4ab9-bda5-59ebb99e9f5b">916-5445</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_d3732cf2-0aa7-4303-80ee-2bad90413315"
      id="F_202f228c-2458-4698-8e3b-bfc148f5a9c0">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_d3732cf2-0aa7-4303-80ee-2bad90413315"
      id="F_23e5881c-e5aa-45c0-81cf-7c6971cc5c23">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_d3732cf2-0aa7-4303-80ee-2bad90413315"
      id="F_85c90dba-4990-457a-8657-2eebff7524fe">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_d3732cf2-0aa7-4303-80ee-2bad90413315"
      id="F_a841a9d5-5e83-41aa-a536-e6b63dfc2ab6">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_d3732cf2-0aa7-4303-80ee-2bad90413315"
      id="F_4e0d95cb-2bf5-4067-b6bd-e653281c64b9">Common Stock, $0.01 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_d3732cf2-0aa7-4303-80ee-2bad90413315"
      id="F_ef09d946-8742-4910-ab82-489b2edba825">CADL</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_d3732cf2-0aa7-4303-80ee-2bad90413315"
      id="F_c26c6a40-9a6d-41c5-b084-807908ecaf1e">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_d3732cf2-0aa7-4303-80ee-2bad90413315"
      id="F_51331941-e85a-46d3-8931-d4a58772fede">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_d3732cf2-0aa7-4303-80ee-2bad90413315"
      id="F_b2a90c0c-b413-4038-b0e4-66a1b8147c55">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
